EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetics of piperacillin/tazobactam in critically ill pediatric patients

Tavey Dorofaeff iD, María Patricia Hernández-Mitre iD, Xin Liu iD, Yarmarly C Guerra Valero, Mark G Coulthard iD, Jeffrey Lipman iD, Steven C Wallis iD, Diane L Maresco-Pennisi iD, Suzane L Parker iD, Jason A Roberts

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00272-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Tavey Dorofaeff und 9 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, The University of Queensland, Brisbane, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Piperacillin, Tazobactam Drug Combination, Penicillanic Acid. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Health Queensland, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Piperacillin-tazobactam is commonly used in critically ill pediatric patients; however, standard dosing regimens may not reliably achieve maximally effective exposures in this population. To characterize the population pharmacokinetics of piperacillin-tazobactam in critically ill pediatric patients and evaluate the adequacy of commonly used dosing regimens, plasma concentrations were obtained around a single dose of piperacillin-tazobactam in critically ill pediatric patients aged 1 month to 12 years. A simultaneous population pharmacokinetic model for piperacillin and tazobactam was developed using nonlinear mixed-effects modeling. Monte Carlo simulations were performed to assess the probability of target attainment (PTA) for short, extended, and continuous infusion regimens across a range of ages and renal function states. Dosing adequacy was defined by simultaneous attainment of target drug exposures for piperacillin (100%fT > MIC) and tazobactam (85%fT > 2 mg/L). Thirty-one patients contributed 102 plasma samples, of which only 22.6% of patients achieved simultaneous piperacillin-tazobactam target exposures, considering a piperacillin MIC of 16 mg/L. Renal function and infusion duration were the primary determinants of attainment of target attainment. Standard short infusions frequently failed to achieve combined target exposures, particularly in patients with preserved renal function or augmented renal clearance (ARC). Extended infusions improved PTA, but remained suboptimal at higher MICs. Continuous infusion consistently achieved the highest target drug exposures across all simulated scenarios. Short intermittent piperacillin-tazobactam infusions and even extended infusions often result in suboptimal exposure in critically ill pediatric patients. Continuous infusion represents a rational dosing strategy to improve combined target attainment, particularly in children with preserved or ARC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationPenicillanic AcidHumansCritical IllnessChild, PreschoolChildInfantPiperacillinMicrobial Sensitivity TestsFemaleMaleMonte Carlo Method

Stichwörter der Autor:innen

critically ill childrenintensive carepediatricspharmacokineticspiperacillin-tazobactam

Substanzen

Anti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationPiperacillinPenicillanic Acid

Autor:innen und Institutionen

  • Frazer Institute, The University of Queensland, Brisbane, Australia.
  • Department of Pediatric Intensive Care, Queensland Children's Hospital, Brisbane, Australia.
  • Faculty of Health Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia.
  • Jamieson Trauma Institute, Royal Brisbane & Women's Hospital, Brisbane, Australia.
  • Division of Anesthesia Critical Care, Pain and Emergency Medicine, UR-UM104 IMAGINE, University of Montpellier, Nimes University Hospital, Montpellier, France.
  • Department of Intensive Care Medicine, Royal Brisbane & Women's Hospital, Brisbane, Australia.

ORCID-Profile: Tavey Dorofaeff, María Patricia Hernández-Mitre, Xin Liu, Mark G Coulthard, Jeffrey Lipman, Steven C Wallis, Diane L Maresco-Pennisi, Suzane L Parker

Förderung

  • Children's Health Queensland
  • National Health and Medical Research Council

Zitieren

APA

Dorofaeff, T., Hernández-Mitre, M. P., Liu, X., Guerra Valero, Y. C., Coulthard, M. G., Lipman, J., Wallis, S. C., Maresco-Pennisi, D. L., Parker, S. L., & Roberts, J. A. (2026). Population pharmacokinetics of piperacillin/tazobactam in critically ill pediatric patients. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00272-26

Vancouver

Dorofaeff T, Hernández-Mitre MP, Liu X, Guerra Valero YC, Coulthard MG, Lipman J, et al. Population pharmacokinetics of piperacillin/tazobactam in critically ill pediatric patients. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00272-26

BibTeX
@article{Dorofaeff2026,
  author = {Dorofaeff, Tavey and Hernández-Mitre, María Patricia and Liu, Xin and Guerra Valero, Yarmarly C and Coulthard, Mark G and Lipman, Jeffrey and Wallis, Steven C and Maresco-Pennisi, Diane L and Parker, Suzane L and Roberts, Jason A},
  title = {Population pharmacokinetics of piperacillin/tazobactam in critically ill pediatric patients},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00272-26}
}
Kostenlos starten →